Trevor Lowenthal | TalkMarkets | Page 1

Trevor Lowenthal

Seeking Alpha Contributor
Contributor's Links: Seeking Alpha Profile
With emphasis on biotechnology, Trevor focuses his portfolio on undervalued micro and small-cap companies. Through his position with TalkMarkets, he hopes to elucidate undervalued companies that are exploring revolutionary treatment modalities for a wide spectrum of rare and devastating medical ...more
Following: 18 Followers: 116

All Contributions

Latest Posts
1 to 10 of 10 Posts
Baxter On A Roll -- Wins Approval For OBIZUR
Friday, October 24, 2014 5:31 PM EDT
Baxter continues to enhance the growth prospects. Back-to-back approvals of three important treatment supports the bullish thesis.
In this article: BAX
Read
OXiGENE: First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin
Wednesday, October 8, 2014 12:04 PM EDT
OXiGENE announces that the first patient has been enrolled in the Phase 1b/2 study of fosbretabulin in combination with Votrient(TM) (pazopanib) in patients with recurrent ovarian cancer.
In this article: OXGN
Read
A Recap Of My MannKind Experience
Friday, October 3, 2014 3:31 AM EDT
Various commentators questioned my integrity and motives for my continued coverage of MannKind. This article hopes to set the record straight.
In this article: MNKD
Read
Opexa Expands Patent Portfolio -- Hints At New Indications
Monday, September 29, 2014 12:50 PM EDT
With the announcement of allowance of its 98th patent, Opexa hints at expanding to new indications.
In this article: OPXA
Read
BioLife Elevates Guidance With 130 Embedded Clinical Trials
Sunday, September 28, 2014 4:48 PM EDT
Overall, I calculate that BioLife is now supported to generate approximately $23 million in revenue by 2018.
In this article: BLFS
Read
Opexa Cancels Offering -- Sends Mixed Messages To Shareholders
Tuesday, September 16, 2014 3:21 PM EDT
Opexa terminates offering announced yesterday.
In this article: OPXA
Read
Is Now The Time To Buy China Biologics?
Monday, July 7, 2014 11:15 AM EDT
China Biologics has dipped, providing investors an opportunity to buy shares.
In this article: BAX, NVO, CBPO
Read
Is Inovio A Biotech Gem Or A Dud?--Win Either Way
Wednesday, June 18, 2014 9:12 AM EDT
Will Inovio climb or will it tumble? Regardless, here is a strategy that enables you to profit from explosive movement in either direction.
In this article: INO
Read
Interview With RXi Pharmaceuticals Management
Thursday, May 29, 2014 11:50 PM EDT
Interview with Dr. Geert Cauwenbergh, President and Chief Executive Officer of RXi.
In this article: RXII
Read
Interview With Endocyte Management
Thursday, May 29, 2014 12:48 PM EDT
Interview excerpts with Mike Sherman, CFO of Endocyte.
In this article: ECYT
Read
1 to 10 of 10 Posts